New therapeutic algorithm of Type 2 diabetes: Lights and shadows

Journal of Endocrinological Investigation

Volumn 34, Issue 1, 2011, Pages 65-68

  Consoli, A ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Hypoglycemic agents; Treatment strategies; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

ALGORITHM; BLOOD GLUCOSE MONITORING; GLUCOSE TOLERANCE; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

EID: 79955457610     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/bf03346697     Document Type: Note

References (25)

1. Texas Diabetes Council. Glycemic control algorithm for type 2 diabetes mellitus in children and adults. Available at: http:// www.dshs.state.tx.us/ diabetes/pdf/algorithms/type%202%20glycemic%20control.pdf. Last update: October 2005.
2. Jellinger P, Davidson J, Blonde L, et al. for the ACE/ACCE Diabetes Road Map Task Force. Road map to achieve glucemic control: naive to therapy (type 2). Available at: http://www.medscape.com/viewarticle/559463.
3. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009,15: 540-59.
4. Canadian Diabetes Association. Canadian Diabetes Association 2008 clinical pactice guidelines. Can J Diab 2008, 32: S1-201.
5. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010, 33 (Suppl 1): S11-61.
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32: 193-203.
7. Kahn R, Gale EA. Gridlocked guidelines for diabetes. Lancet 2010, 375: 2203-4.
8. Schünemann HJ, Fretheim A, Oxman AD; WHO Advisory Committee on Health Research. Improving the use of research evidence in guideline development: 1. Guidelines for guidelines. Health Res Policy Syst 2006, 4: 13.
9. Atkins D, Best D, Briss PA, et al; GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004, 328: 1490.
10. American Diabetes Association. Clinical practice recommendations 2008. Diabetes Care 2008, 31: S1-2.
11. Schernthaner G, Barnett AH, Betteridge DJ, et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 53: 1258-69.
12. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006, 49: 1711-21.
13. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9: 194-205.
14. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009, 11: 157-66.
15. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007, 147: 386-99. (Pubitemid 351664540)
16. Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008, 79: 196-203.
17. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298: 194-206. (Pubitemid 47057766)
18. Kahn SE, Haffner SM, Heise MA, et al; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355: 2427-43. (Pubitemid 44903747)
19. Garber A, Henry R, Ratner R, et al; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373: 473-81.
20. McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab 12: 431-6.
21. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58: 773-95.
22. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368: 1096-105.
23. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005, 59: 1345-55.
24. Bailey CJ, Blonde L, Del Prato S, Leiter LA, Nesto R; Global Partnership for Effective Diabetes Management. What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management. Diab Vasc Dis Res 2009, 6: 283-7.
25. Gale EA. Who needs the diabetes specialist physician? Diabetologia 2008, 51: 700-2.